FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3129187816> ?p ?o ?g. }

• W3129187816 abstract "18F labelled PSMA-1007 presents promising results in detecting prostate cancer (PC), while some pitfalls exists meanwhile. An intra-individual comparison of 18F-FDG and 18F-PSMA-1007 in patients with prostate cancer were aimed to be performed in the present study. Then, the pitfalls of 18F-PSMA-1007 PET/CT in imaging of patients with prostate cancer were analyzed.21 prostate cancer patients underwent 18F-PSMA-1007 PET/CT as well as 18F-FDG PET/CT before treatment. All positive lesions were noticed in both 18F-PSMA-1007 PET/CT and 18F-FDG PET/CT, then differentiated PC metastasis from benign lesions. the SUVmax, SUVmean and TBR of lesions, up to 10 metastases and 10 benign lesions per patients were recorded (5 for bone, 5 for soft tissue metastasis ). The distribution of positive lesions were analyzed for two imaging. Detection rates, SUVmax, SUVmean and TBR in 18F-PSMA-1007 PET/CT and 18F-FDG PET/CT were compared, respectively. The optimal cut-off values of SUVmax, SUVmean for metastases vs. benign lesions was found through areas under ROC in 18F-PSMA-1007.The detection rates of primary lesions in 18F-PSMA-1007 PET/CT was higher than that of 18F-FDG PET/CT(100% (21/21) vs. 67%(14/21)). For extra- prostatic lesions, 18F-PSMA-1007 PET/CT revealed 124 positive lesions, 49(49/124, 40%) attributed to a benign origin; 18F-FDG PET/CT revealed 68 positive lesions, 14(14/68, 21%) attributed to a benign origin. The SUVmax, SUVmean, TBR of primary tumor in 18F-PSMA-1007 PET/CT was higher than that in 18F-FDG PET/CT (15.20 vs. 4.20 for SUVmax; 8.70 vs. 2.80 for SUVmean; 24.92 vs. 4.82 for TBR, respectively); The SUVmax, SUVmean, TBR of metastases in 18F-PSMA-1007 PET/CT was higher than that in 18F-FDG PET/CT (10.72 vs. 4.42 for SUVmax; 6.67 vs. 2.59 for SUVmean; The TBR of metastases was 13.3 vs. 7.91). For 18F-FDG PET/CT, the SUVmax, SUVmean in metastases was higher than that in benign lesions (4.42 vs. 3.04 for SUVmax, 2.59 vs. 1.75 for SUVmean, respectively). Similarly, for 18F-PSMA-1007 PET/CT, the SUVmax, SUVmean in metastases was significantly higher than that in benign lesions(10.72 vs. 3.14 for SUVmax, 6.67 vs. 1.91 for SUVmean, respectively), ROC suggested that SUVmax=7.71, SUVmean=5.35 might be the optimal cut-off values for metastases vs. benign lesions.The pilot study suggested that 18F-PSMA-1007 showed superiority over 18F-FDG because its high detecting rate of PC lesions and excellent tumor uptake. While non-tumor uptake in 18F-PSMA-1007 may lead to misdiagnosis, recognizing these pitfalls and careful analysis can improve the accuracy of diagnosis." @default.
• W3129187816 created "2021-02-15" @default.
• W3129187816 creator A5003944461 @default.
• W3129187816 creator A5009998424 @default.
• W3129187816 creator A5017007472 @default.
• W3129187816 creator A5017107576 @default.
• W3129187816 creator A5024628055 @default.
• W3129187816 creator A5025700100 @default.
• W3129187816 creator A5044387127 @default.
• W3129187816 creator A5053835044 @default.
• W3129187816 creator A5053874839 @default.
• W3129187816 creator A5055688170 @default.
• W3129187816 creator A5075303600 @default.
• W3129187816 date "2021-02-01" @default.
• W3129187816 modified "2023-09-30" @default.
• W3129187816 title "Intra-Individual Comparison of 18F-PSMA-1007 and 18F-FDG PET/CT in the Evaluation of Patients With Prostate Cancer" @default.
• W3129187816 cites W1903999661 @default.
• W3129187816 cites W1973942000 @default.
• W3129187816 cites W2026704767 @default.
• W3129187816 cites W2042285687 @default.
• W3129187816 cites W2073380728 @default.
• W3129187816 cites W2103832652 @default.
• W3129187816 cites W2137670219 @default.
• W3129187816 cites W2138140091 @default.
• W3129187816 cites W2144904402 @default.
• W3129187816 cites W2410782911 @default.
• W3129187816 cites W2460323461 @default.
• W3129187816 cites W2470255787 @default.
• W3129187816 cites W2525349940 @default.
• W3129187816 cites W2541665535 @default.
• W3129187816 cites W2554535346 @default.
• W3129187816 cites W2561138750 @default.
• W3129187816 cites W2581557899 @default.
• W3129187816 cites W2740524391 @default.
• W3129187816 cites W2750790860 @default.
• W3129187816 cites W2765104426 @default.
• W3129187816 cites W2776187196 @default.
• W3129187816 cites W2785597822 @default.
• W3129187816 cites W2791618202 @default.
• W3129187816 cites W2792170023 @default.
• W3129187816 cites W2883030921 @default.
• W3129187816 cites W2889646458 @default.
• W3129187816 cites W2898715328 @default.
• W3129187816 cites W2953857927 @default.
• W3129187816 cites W2976273049 @default.
• W3129187816 cites W3029205023 @default.
• W3129187816 doi "https://doi.org/10.3389/fonc.2020.585213" @default.
• W3129187816 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7884904" @default.
• W3129187816 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33604285" @default.
• W3129187816 hasPublicationYear "2021" @default.
• W3129187816 type Work @default.
• W3129187816 sameAs 3129187816 @default.
• W3129187816 citedByCount "18" @default.
• W3129187816 countsByYear W31291878162021 @default.
• W3129187816 countsByYear W31291878162022 @default.
• W3129187816 countsByYear W31291878162023 @default.
• W3129187816 crossrefType "journal-article" @default.
• W3129187816 hasAuthorship W3129187816A5003944461 @default.
• W3129187816 hasAuthorship W3129187816A5009998424 @default.
• W3129187816 hasAuthorship W3129187816A5017007472 @default.
• W3129187816 hasAuthorship W3129187816A5017107576 @default.
• W3129187816 hasAuthorship W3129187816A5024628055 @default.
• W3129187816 hasAuthorship W3129187816A5025700100 @default.
• W3129187816 hasAuthorship W3129187816A5044387127 @default.
• W3129187816 hasAuthorship W3129187816A5053835044 @default.
• W3129187816 hasAuthorship W3129187816A5053874839 @default.
• W3129187816 hasAuthorship W3129187816A5055688170 @default.
• W3129187816 hasAuthorship W3129187816A5075303600 @default.
• W3129187816 hasBestOaLocation W31291878161 @default.
• W3129187816 hasConcept C121608353 @default.
• W3129187816 hasConcept C126322002 @default.
• W3129187816 hasConcept C126838900 @default.
• W3129187816 hasConcept C127077266 @default.
• W3129187816 hasConcept C2775842073 @default.
• W3129187816 hasConcept C2776235491 @default.
• W3129187816 hasConcept C2779013556 @default.
• W3129187816 hasConcept C2780192828 @default.
• W3129187816 hasConcept C2989005 @default.
• W3129187816 hasConcept C71924100 @default.
• W3129187816 hasConceptScore W3129187816C121608353 @default.
• W3129187816 hasConceptScore W3129187816C126322002 @default.
• W3129187816 hasConceptScore W3129187816C126838900 @default.
• W3129187816 hasConceptScore W3129187816C127077266 @default.
• W3129187816 hasConceptScore W3129187816C2775842073 @default.
• W3129187816 hasConceptScore W3129187816C2776235491 @default.
• W3129187816 hasConceptScore W3129187816C2779013556 @default.
• W3129187816 hasConceptScore W3129187816C2780192828 @default.
• W3129187816 hasConceptScore W3129187816C2989005 @default.
• W3129187816 hasConceptScore W3129187816C71924100 @default.
• W3129187816 hasFunder F4320333335 @default.
• W3129187816 hasLocation W31291878161 @default.
• W3129187816 hasLocation W31291878162 @default.
• W3129187816 hasLocation W31291878163 @default.
• W3129187816 hasOpenAccess W3129187816 @default.
• W3129187816 hasPrimaryLocation W31291878161 @default.
• W3129187816 hasRelatedWork W1980245127 @default.
• W3129187816 hasRelatedWork W2068814703 @default.
• W3129187816 hasRelatedWork W2070705913 @default.
• W3129187816 hasRelatedWork W2077640666 @default.
• W3129187816 hasRelatedWork W2736007806 @default.

• next